Christina Charles-Schoeman, Patrick Zueger, Erin McDearmon-Blondell, Siran Fang, Yi Peng, Manish Jain, John Tesser

In this analysis of administrative health care claims and electronic medical record data (2016–2023), treatment response was evaluated among patients with rheumatoid arthritis (RA) on a first-line tumor necrosis factor inhibitor (TNFi). The study included patients with moderate/high disease activity (MDA/HDA) at TNFi initiation who remained on first-line TNFi for ≥12 months. Treatment response was defined per the Clinical Disease Activity Index (CDAI) as low disease activity (LDA) or remission (CDAI≤10). Following first-line TNFi initiation, 34.1% of patients (n/N=414/1215) achieved LDA/remission at 3 months, and 40.8% (n/N=563/1381) achieved LDA/remission at 6 months. Among patients in MDA/HDA at 6 months, 80% remained in MDA/HDA at 12 months. Thus, the majority of those who did not achieve an initial TNFi response also did not achieve a subsequent response at 12 months.

The Medical Affairs + Health Impact department of AbbVie Inc. is the copyright owner of this presentation and has paid RheumNow to host this content. AbbVie is solely responsible for all written content within this presentation.

© 2025 AbbVie Inc. All rights reserved. ABBV-US-01932-MC v1.0 Approved April 2025